UA80433C2 - Fluorosiloxane matrix controlled diffusion drug delivery system - Google Patents

Fluorosiloxane matrix controlled diffusion drug delivery system Download PDF

Info

Publication number
UA80433C2
UA80433C2 UAA200500490A UA2005000490A UA80433C2 UA 80433 C2 UA80433 C2 UA 80433C2 UA A200500490 A UAA200500490 A UA A200500490A UA 2005000490 A UA2005000490 A UA 2005000490A UA 80433 C2 UA80433 C2 UA 80433C2
Authority
UA
Ukraine
Prior art keywords
methacrylate
agents
release
group
controlled diffusion
Prior art date
Application number
UAA200500490A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA80433C2 publication Critical patent/UA80433C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
    • C08G77/24—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen halogen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/04—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/20—Polysiloxanes containing silicon bound to unsaturated aliphatic groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/70—Siloxanes defined by use of the MDTQ nomenclature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA200500490A 2002-06-19 2003-06-16 Fluorosiloxane matrix controlled diffusion drug delivery system UA80433C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/175,716 US20040043067A1 (en) 2002-06-19 2002-06-19 Fluorosiloxane matrix controlled diffusion drug delivery systems
PCT/US2003/019026 WO2004000288A1 (en) 2002-06-19 2003-06-16 Fluorosiloxane matrix controlled diffusion drug delivery system

Publications (1)

Publication Number Publication Date
UA80433C2 true UA80433C2 (en) 2007-09-25

Family

ID=29999052

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200500490A UA80433C2 (en) 2002-06-19 2003-06-16 Fluorosiloxane matrix controlled diffusion drug delivery system

Country Status (17)

Country Link
US (1) US20040043067A1 (de)
EP (1) EP1515705B1 (de)
JP (1) JP2005530842A (de)
CN (1) CN1662227A (de)
AU (1) AU2003238247A1 (de)
BR (1) BR0311963A (de)
CA (1) CA2489987A1 (de)
CZ (1) CZ200537A3 (de)
DE (1) DE60306379T2 (de)
ES (1) ES2261947T3 (de)
MX (1) MXPA04012897A (de)
PL (1) PL375000A1 (de)
RU (1) RU2307667C2 (de)
TW (1) TW200404569A (de)
UA (1) UA80433C2 (de)
WO (1) WO2004000288A1 (de)
ZA (1) ZA200409979B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005269988B2 (en) 2004-07-02 2012-02-02 Mati Therapeutics Inc. Treatment medium delivery device and methods for delivery
US7544371B2 (en) * 2005-12-20 2009-06-09 Bausch + Lomb Incorporated Drug delivery systems
US20070148244A1 (en) * 2005-12-22 2007-06-28 Kunzler Jay F Drug delivery systems
US20070218103A1 (en) * 2006-03-15 2007-09-20 Bausch & Lomb Incorporated Rate controlled release of a pharmaceutical agent in a biodegradable device
US20070218104A1 (en) * 2006-03-15 2007-09-20 Bausch & Lomb Incorporation Rate controlled release of a pharmaceutical agent in a biodegradable device
KR20090006153A (ko) 2006-03-31 2009-01-14 큐엘티 플러그 딜리버리, 인코포레이티드 비루관계에 대한 약물 전달 방법, 구조, 및 조성물
US7579021B2 (en) * 2006-09-27 2009-08-25 Bausch & Lomb Incorporated Drug delivery systems based on degradable cationic siloxanyl macromonomers
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US9011361B2 (en) 2007-09-07 2015-04-21 Mati Therapeutics Inc. Lacrimal implant detection
JP5599712B2 (ja) * 2007-10-05 2014-10-01 インターフェース バイオロジクス，インコーポレーテッド オリゴフッ素化架橋ポリマーおよびそれの使用
BRPI1007318A2 (pt) * 2009-01-23 2019-04-09 Qlt Inc. distribuição com liberação sustentada de um ou mais agentes.
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US20130053794A1 (en) 2011-08-29 2013-02-28 Suzanne Cadden Sustained release delivery of active agents to treat glaucoma and ocular hypertension

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
CA1295941C (en) * 1985-08-16 1992-02-18 Rajan Bawa Sustained-release formulation comprising a hydrophobic polymer system
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US4882377A (en) * 1988-09-21 1989-11-21 Dow Corning Corporation Low-viscosity pressure-adherent silicone elastomer compositions
US5321108A (en) * 1993-02-12 1994-06-14 Bausch & Lomb Incorporated Fluorosilicone hydrogels
US5463010A (en) * 1993-11-12 1995-10-31 Surface Engineering Technologies, Division Of Innerdyne, Inc. Hydrocyclosiloxane membrane prepared by plasma polymerization process
US6322815B1 (en) * 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
ES2164265T3 (es) * 1995-12-07 2002-02-16 Bausch & Lomb Unidades monomericas utiles para reducir el modulo de hidrogeles de silicona.
US5714557A (en) * 1995-12-07 1998-02-03 Bausch & Lomb Incorporated Monomeric units useful for reducing the modulus of low water polymeric silicone compositions
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
JP4496316B2 (ja) * 1997-04-03 2010-07-07 エーザイ インコーポレイテッド 生分解性テレフタレートポリエステル−ポリホスフェートポリマー、組成物、物品、並びにその製造及び使用方法
US5908996A (en) * 1997-10-24 1999-06-01 Timewarp Technologies Ltd Device for controlling a musical performance
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection

Also Published As

Publication number Publication date
CZ200537A3 (cs) 2006-04-12
MXPA04012897A (es) 2005-03-31
PL375000A1 (en) 2005-11-14
CN1662227A (zh) 2005-08-31
EP1515705B1 (de) 2006-06-21
ZA200409979B (en) 2006-07-26
RU2005100840A (ru) 2005-07-10
HK1070826A1 (en) 2005-06-30
BR0311963A (pt) 2005-03-29
RU2307667C2 (ru) 2007-10-10
DE60306379T2 (de) 2007-06-14
JP2005530842A (ja) 2005-10-13
AU2003238247A1 (en) 2004-01-06
TW200404569A (en) 2004-04-01
WO2004000288A1 (en) 2003-12-31
DE60306379D1 (de) 2006-08-03
US20040043067A1 (en) 2004-03-04
CA2489987A1 (en) 2003-12-31
EP1515705A1 (de) 2005-03-23
ES2261947T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
JP5694664B2 (ja) 生分解性眼用インプラント及び眼の病気を治療する方法
EP3263574A1 (de) Fluid zur aufnahme von kontaktlinsen
Zou et al. A thermo-sensitive, injectable and biodegradable in situ hydrogel as a potential formulation for uveitis treatment
US12503553B2 (en) Biodegradable drug-polymer conjugate
EP1515705B1 (de) Diffusionskontrolliertes wirkstoffabgabesystem mit fluorosiloxan-matrix
TW200816966A (en) Low-tack ophthalmic and otorhinolaryngological device materials
US7544371B2 (en) Drug delivery systems
CN114907540A (zh) 聚氨酯类高分子聚合物及其制备方法，聚氨酯类高分子聚合物水凝胶、试剂盒及其应用
JP2022501365A (ja) ドラッグデリバリーのための多孔質生体吸収性放射線不透過性塞栓ミクロスフェア
US20060078592A1 (en) Drug delivery systems
EP3936113A1 (de) Hydrophile, abbaubare mikrokugel zur abgabe von travoprost
US11696955B2 (en) Drug-polymer conjugate
HK1070826B (en) Fluorosiloxane matrix controlled diffusion drug delivery system
US8920841B2 (en) Biodegradable polymer system
US20070148244A1 (en) Drug delivery systems
KR20050021025A (ko) 플루오로실록산 매트릭스 조절 확산 약물 전달계
Pusch Strategies of preparing transparent latices with application to the synthesis of transparent hydrogels for intraocular lenses
HK40091307A (en) Novel polymers and uses thereof
Perry A Poly-N-isopropylacrylamide Based Hydrogel as a Novel Material for Vitreous Replacement
Chesterman Reversibly photo-crosslinkable polycarbonate-based polymersomes for drug encapsulation and delivery